Enlivex Cuts Workforce About 60% in Cost Reduction Plan
Enlivex will wind down non-clinical R&D, focus resources on its Phase 2b Allocetra knee osteoarthritis trial and reduce management salaries. The company expects topline six-month trial data by mid-2027.